Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Expressing Solid Tumors”

59 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 59 results

Early research (Phase 1)Looking for participantsNCT05819684
What this trial is testing

SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 133
Testing effectiveness (Phase 2)UnknownNCT05805956
What this trial is testing

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Who this might be right for
Advanced Solid TumorAdvanced Lung CancerAdvanced Gastric Carcinoma+1 more
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 105
Testing effectiveness (Phase 2)Looking for participantsNCT07022002
What this trial is testing

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Who this might be right for
Locally Advanced, Recurrent or Metastatic Malignancies
Shenyang Sunshine Pharmaceutical Co., LTD. 340
Testing effectiveness (Phase 2)Looking for participantsNCT07192432
What this trial is testing

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Who this might be right for
HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc. 27
Testing effectiveness (Phase 2)Study completedNCT02386501
What this trial is testing

Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Who this might be right for
HER2 Expressing Solid Tumors
Advaxis, Inc. 12
Early research (Phase 1)Study completedNCT04319757
What this trial is testing

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Who this might be right for
Locally Advanced Solid TumorMetastatic CancerSolid Tumor+2 more
Acepodia Biotech, Inc. 12
Early research (Phase 1)Study completedNCT00084513
What this trial is testing

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Fox Chase Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT00900627
What this trial is testing

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Cancer
AstraZeneca 330
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Early research (Phase 1)Study completedNCT02576548
What this trial is testing

MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

Who this might be right for
HER2 Expressing Breast or Gastric/Stomach Cancers
MedImmune LLC 47
Early research (Phase 1)Study completedNCT01730118
What this trial is testing

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Who this might be right for
Breast NeoplasmsBreast CancerAdenocarcinomas+1 more
National Cancer Institute (NCI) 33
Early research (Phase 1)Active Not RecruitingNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 120
Early research (Phase 1)Looking for participantsNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Large-scale testing (Phase 3)Looking for participantsNCT06504732
What this trial is testing

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

Who this might be right for
Stomach NeoplasmsSolid Tumor
SUNHO（China）BioPharmaceutical CO., Ltd. 90
Early research (Phase 1)WithdrawnNCT06560138
What this trial is testing

A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

Who this might be right for
HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors
Atridia Pty Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT07228247
What this trial is testing

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Who this might be right for
Solid Tumors, Adult
Hutchmed 147
Testing effectiveness (Phase 2)Ended earlyNCT01569412
What this trial is testing

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Who this might be right for
Her2/Neu Positive Advanced Solid Tumors
Krankenhaus Nordwest 14
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Load More Results